Pain Reduction Improves Adherence, Quality of Life, and Work Capacity in Rheumatoid Arthritis Patients Receiving Baricitinib: Czech ATTRA Registry Analysis

Treatment with baricitinib provided sustained pain reduction and decreased disease activity in patients with RA. Findings highlight the need for pain-focused treatment goals and suggest earlier intervention may enhance persistence and QoL. Work limitations persisted, highlighting the need for flexible employment policies.